Grufity logoGrufity logo

MRNA

181.48USD+5.57(+3.17%)Market Closed

Moderna Inc

Market Summary

USD181.48+5.57Market Closed
3.17%

MRNA Alerts

MRNA Stock Price

RSI Chart

Valuation

Market Cap

59.1B

Price/Earnings

4.2

Price/Sales

2.57

Price/Cashflow

6.12

MarketCap/EBT

3.77

Price/Sales

Profitability

EBT Margin

68.12%

Return on Equity

78.15%

Return on Assets

53.97%

Fundamentals

Revenue

Revenue (TTM)

23.0B

Revenue Y/Y

9.07%

Revenue Q/Q

-21.71%

Earnings

Earnings (TTM)

14.1B

Earnings Y/Y

-20.97%

Earnings Q/Q

-39.92%

Price Action

52 Week Range

115.03321.31
(Low)(High)

Last 7 days

3.4%

Last 30 days

22.7%

Last 90 days

31.6%

Trailing 12 Months

-39.5%

Financial Health

Current Ratio

1.99

Investor Care

Buy Backs (1Y)

3.08%

Diluted EPS (TTM)

32.81

Peers (Alternatives to Moderna)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
146.5B
26.3B
6.86% 46.41%
22.27
5.55
2.18% 21.86%
99.4B
27.1B
14.32% 33.87%
24.02
3.61
-1.26% -54.91%
59.1B
23.0B
22.70% -39.52%
4.2
2.57
227.55% 302.16%
41.3B
10.4B
7.38% 30.80%
14.4
3.98
-6.64% 85.32%
11.1B
1.4B
3.89% 57.25%
905.99
8.52
29.86% -86.92%
MID-CAP
3.7B
112.4M
6.18% -26.69%
-12.87
32.5
-41.50% -607.58%
3.4B
-
7.39% -35.47%
-14.65
59.51
215916.67% 21.41%
2.1B
68.3M
4.34% -60.25%
-8.33
30.98
42.18% -19.70%
2.0B
432.8M
45.87% -20.63%
29.99
4.9
1042.97% 128.67%
SMALL-CAP
1.8B
1.8B
-19.41% -89.80%
-1.22
1.39
53.41% -22.97%
1.6B
69.7M
-4.82% -76.34%
-3.15
20.84
745.14% -7.72%
891.0M
3.2M
5.78% -29.88%
-6.7
275.59
11.14% -46.59%
692.0M
114.2M
-14.32% -56.80%
-4.02
6.06
-17.11% -27.41%
458.1M
-
-17.48% -90.68%
-13.56
44.06
522.71% -129.91%
218.9M
-
-15.58% -80.57%
-2.36
609.63
-71.03% -64.56%

Financials for Moderna

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Revenue1.7%22,99522,60018,47111,8317,020
  S&GA Expenses11.9%848758567445326
  R&D Expenses13.5%2,4332,1441,9912,1021,926
Earnings Before Taxes-3.6%15,66516,25413,2857,6043,820
Net Income-4.0%14,05514,63812,2027,0623,495
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Assets-5.7%26,04327,60924,66920,92316,153
  Current Assets-17.0%13,56316,35016,07113,42510,969
    Cash Equivalents-43.1%2,8735,0486,8485,5505,603
  Inventory-1.1%1,9211,9421,441965643
Liabilities-23.5%8,05810,53410,52410,7999,449
  Current Liabilities-26.3%6,8129,2389,1289,9578,840
Shareholder's Equity5.3%17,98517,07514,14510,1246,704
  Retained Earnings16.1%15,81213,6159,9585,0901,757
  Additional Paid-In Capital-33.8%2,4133,6444,2115,0034,931
Shares Outstanding-2.0%392400403405403
Float-80,800----
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Cashflow From Operations-28.0%9,65313,41213,62011,5749,191
  Share Based Compensation9.6%171156142131114
Cashflow From Investing22.2%-9,538.00-12,264.00-8,523.00-7,575.13-5,426.39
Cashflow From Financing-84.6%-2,844.00-1,541.00-873.004476
  Buy Backs87.7%2,7781,48085700
* denotes actual numbers (not divided by Millions)

Risks

What is the probability of a big loss on MRNA?

99.0%


Probability that Moderna stock will be more than 20% underwater in next one year

80.1%


Probability that Moderna stock will be more than 30% underwater in next one year.

50.2%


Probability that Moderna stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does MRNA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Moderna was unfortunately bought at previous high price.

Returns

Cumulative Returns on MRNA

104.6%


3-Year Cumulative Returns

Which funds bought or sold MRNA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Eagle Bay Advisors LLC
ADDED
33.21
4,002
44,000
0.03%
2022-11-23
Aurora Investment Counsel
REDUCED
-51.03
-1,476,000
866,000
0.66%
2022-11-23
Toroso Investments, LLC
ADDED
8.25
-417,000
3,599,000
0.15%
2022-11-22
B. Riley Wealth Advisors, Inc.
ADDED
38.61
146,000
1,136,000
0.03%
2022-11-22
IHT Wealth Management, LLC
-
-
-39,000
290,000
0.02%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
33,873,000
33,873,000
0.40%
2022-11-22
CONTINENTAL INVESTORS SERVICES, INC.
NEW
-
1,496,000
1,496,000
0.06%
2022-11-22
CVA Family Office, LLC
-
-
-8,000
47,000
0.01%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
-15,971,000
67,312,000
0.11%
2022-11-21
FourThought Financial, LLC
-
-
-4,000
20,000
-%

1–10 of 39

Latest Funds Activity

Are funds buying MRNA calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own MRNA

Moderna News

Seeking Alpha

Ocugen Stock: Still Struggling (NASDAQ:OCGN).94 minutes ago

The Motley Fool

The Motley Fool

MRNA Fair Value

Recent SEC filings of Moderna

View All Filings
Date Filed Form Type Document
Nov 30, 2022
4
Insider Trading
Nov 30, 2022
4
Insider Trading
Nov 28, 2022
4
Insider Trading
Nov 18, 2022
4
Insider Trading
Nov 18, 2022
4
Insider Trading
Nov 18, 2022
4
Insider Trading
Nov 14, 2022
4
Insider Trading
Nov 14, 2022
4
Insider Trading
Nov 14, 2022
4
Insider Trading
Nov 10, 2022
4
Insider Trading

Latest Insider Trading transactions for MRNA

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-12-01
Bancel Stephane
SOLD
-1,734,100
173.41
-10,000
Chief Executive Officer
2022-12-01
Bancel Stephane
SOLD
-7,239,070
180.977
-40,000
Chief Executive Officer
2022-12-01
Bancel Stephane
ACQUIRED
39,600
0.99
40,000
Chief Executive Officer
2022-11-30
Andres Juan
ACQUIRED
41,860
20.93
2,000
See remarks
2022-11-30
Bancel Stephane
SOLD
-6,891,820
172.296
-40,000
Chief Executive Officer
2022-11-30
AFEYAN NOUBAR
SOLD
-1,735,200
173.52
-10,000
-
2022-11-30
Bancel Stephane
ACQUIRED
39,600
0.99
40,000
Chief Executive Officer
2022-11-30
Andres Juan
SOLD
-347,040
173.52
-2,000
See remarks
2022-11-29
Andres Juan
SOLD
-141,475
173.803
-814
See remarks
2022-11-29
Hoge Stephen
SOLD
-188,576
173.803
-1,085
President

1–10 of 50

Stéphane Bancel
2700
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. The company has 44 development programs, which includes 26 in clinical trials across seven modalities comprising prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic intracellular therapeutics, and inhaled pulmonary therapeutics. The company has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

MRNA Income Statement

2022-09-30
CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue:    
Total revenue$ 3,364$ 4,969$ 14,179$ 11,260
Operating expenses:    
Cost of sales1,1007223,4981,665
Research and development8205212,0841,343
Selling, general and administrative278168757366
Total operating expenses2,1981,4116,3393,374
Income from operations1,1663,5587,8407,886
Interest income58411311
Other expense, net(7)(10)(33)(22)
Income before income taxes1,2173,5527,9207,875
Provision for income taxes1742191,023541
Net income$ 1,043$ 3,333$ 6,897$ 7,334
Earnings per share:    
Basic (in usd per share)$ 2.67$ 8.27$ 17.41$ 18.25
Diluted (in usd per share)$ 2.53$ 7.70$ 16.46$ 17.00
Weighted average common shares used in calculation of earnings per share:    
Basic (in shares)390404396402
Diluted (in shares)412434419431
Product sales    
Revenue:    
Total revenue$ 3,120$ 4,810$ 13,576$ 10,740
Grant revenue    
Revenue:    
Total revenue144140453473
Collaboration revenue    
Revenue:    
Total revenue$ 100$ 19$ 150$ 47

MRNA Balance Sheet

2022-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 3,027$ 6,848
Investments5,3213,879
Accounts receivable2,6953,175
Inventory2,0771,441
Prepaid expenses and other current assets1,177728
Total current assets14,29716,071
Investments, non-current8,6556,843
Property and equipment, net2,0191,241
Right-of-use assets, operating leases113142
Restricted cash, non-current1412
Deferred tax assets920326
Other non-current assets3834
Total assets26,05624,669
Current liabilities:  
Accounts payable330302
Accrued liabilities1,8561,472
Deferred revenue4,0026,253
Income taxes payable66876
Other current liabilities553225
Total current liabilities6,8079,128
Deferred revenue, non-current175615
Operating lease liabilities, non-current79106
Financing lease liabilities, non-current922599
Other non-current liabilities8176
Total liabilities8,06410,524
Commitments and contingencies (Note 12)
Stockholders’ equity:  
Preferred stock, par value $0.0001; 162 shares authorized as of September 30, 2022 and December 31, 2021; no shares issued or outstanding at September 30, 2022 and December 31, 202100
Common stock, par value $0.0001; 1,600 shares authorized as of September 30, 2022 and December 31, 2021; 387 and 403 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively00
Additional paid-in capital1,4884,211
Accumulated other comprehensive loss(351)(24)
Retained earnings16,8559,958
Total stockholders’ equity17,99214,145
Total liabilities and stockholders’ equity$ 26,056$ 24,669